Harrington Heart & Vascular Institute

Tuesday, March 14, 2017

International Harrington Prize in Medicine jointly awarded to three recipients

CLEVELAND – The fourth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Daniel J. Drucker, MD (Mount Sinai Hospital, Canada), Joel F. Habener, MD (Massachusetts General Hospital, USA) and Jens J. Holst, MD, DMSc (University of Copenhagen, Denmark) for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes.
 
The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio and The American Society for Clinical Investigation (ASCI), honors physician-scientists who have moved science forward with achievements notable for innovation, creativity and potential for clinical application.
 
Drs. Habener and Holst are recognized for their discovery of the hormone glucagon-like peptide 1 (GLP-1) and Dr. Drucker for translating the discovery into breakthrough treatments for diabetes.  The work of these three investigators, and Drucker in particular, has also resulted in the discovery and clinical development of glucagon-like peptide 2 (GLP-2) for intestinal disorders (short bowel syndrome).  

“The work by this trio of investigators that spans the full spectrum from discovery to clinical impact is exemplary,” said Vivian Cheung, MD, Investigator of the Howard Hughes Medical Institute, Professor of Medicine at the University of Michigan, and 2016-2017 President of the ASCI. “This is precisely the type of bench-to-bedside advancements that The Harrington Prize seeks to recognize.”
 
A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed 58 nominations from 49 institutions and five countries before selecting the 2017 recipients.
 
“We are pleased to join with the ASCI to honor Drs. Drucker, Habener and Holst for their contributions to medicine,” said Jonathan Stamler, MD, President of the Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Distinguished Chair in Cardiovascular Innovation at UH Cleveland Medical Center and Case Western Reserve University School of Medicine. “This remarkable trio exemplifies the best in medicine – from fundamental discovery through to breakthrough drugs in the clinic that impact the lives of millions of people around the world.”
 
In addition to sharing a $20,000 honorarium, Drs. Holst, Habener, and Drucker will jointly deliver The Harrington Prize Lecture at the 2017 Association of American Physicians/ASCI/American Physician Scientists Association Joint Meeting on April 21, and publish an essay in The Journal of Clinical Investigation.  
 
Dr. Drucker received his MD from the University of Toronto in 1980, is cu


Thursday, February 09, 2017

Harrington Discovery Institute at University Hospitals opens call for 2018 Harrington Scholar-Innovator Award

CLEVELAND – Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – has opened its annual award competition to fund physician-scientist innovators at major academic medical centers across the country to advance their work toward therapeutic discoveries. This effort is funded with support from University Hospitals and impact philanthropist Ron Harrington and his family, for whom the institute and overarching project are named.  
 
The Harrington Discovery Institute holds an annual competition to identify the nation’s most talented physician-scientists, who will be supported financially and professionally, all to help bridge the gap between breakthrough discovery and promising drugs that can be readied for clinical development.   
 
Applicants have the opportunity to receive:
  • $100,000 guaranteed; opportunity to quality for up to $700,000
  • Drug development and project management support through Harrington Discovery
Institute’s Innovation Support Center
 
Letters of Intent are being accepted thourgh April 5, 2017
 
All applications must be submitted on line at HarringtonDiscovery.org/Grant
 


Tuesday, January 24, 2017

National Institutes of Health honors research leaders from University Hospitals and Case Western Reserve University with prestigious Outstanding Investigator Awards

CLEVELAND – Two internationally recognized medical research leaders from University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine have received Outstanding Investigator Awards from the National Institutes of Health (NIH). The 7-year, $6.7 million dollar awards, which are the highest honor and largest individual support grants conferred by the NIH, will advance promising molecular studies of colon cancer and age-related cardiovascular risks, respectively. The honored physicians are:
 
Sanford Markowitz, MD, PhD, head of the GI Cancer Genetics Program at the Case Comprehensive Cancer Center, Markowitz-Ingalls Professor of Cancer Genetics at Case Western Reserve University School of Medicine and medical oncologist at UH Seidman Cancer Center, received a National Cancer Institute (NCI) Outstanding Investigator Award.  


Mukesh K. Jain, MD, Chief Scientific Officer, University Hospitals and Harrington Discovery Institute; Chief Research Officer, UH Harrington Heart & Vascular Institute; Vice Dean for Medical Sciences and Professor of Medicine, Case Western Reserve University School of Medicine, received a National Heart, Lung, and Blood Institute (NHLBI) Outstanding Investigator Award. 


Wednesday, January 18, 2017

Call for Scholars: Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute expand collaboration

CLEVELAND – Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) are pleased to announce a request for proposals for the 2017 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award supports breakthrough research that promises to prevent, treat or cure Alzheimer’s disease, related dementias and cognitive aging.
 
Applicants have the opportunity to receive:
  • Financial support up to $600,000 over two years
  • Drug development and project management support through Harrington Discovery Institute’s Innovation Support Center
Research without walls: 
“This is a superb opportunity for creative researchers who seek a cure for Alzheimer’s and other dementias,” said Jonathan Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The ADDF-Harrington partnership brings a unique combination of knowhow and resources to advance the most innovative discoveries in Alzheimer’s disease.” 
 
“Our collaboration with Harrington Discovery Institute provides Alzheimer’s researchers critical support needed to move discoveries into clinical trials,” said Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF. “The impact of Alzheimer’s disease is enormous. We need new and diverse approaches to make a difference—and our partnership with Harrington Discovery Institute exemplifies our commitment to advancing these.”
 
Award criteria:
  • The competition is open to academic investigators at accredited medical centers, research institutions and universities in the United States
  • Lead investigator must have an MD or PhD (or equivalent)
  • Proposals should offer creative science or approach to treat, prevent or slow Alzheimer’s disease, other dementias or cognitive aging
 
Please note the following dates:
  • Letters of Intent will be accepted through March 17, 2017
  • Up to 3 awards will be announced by the end of October
  • Applications must be submitted online at AlzDiscovery.org/RFPs
 
 
For more information, please visit HarringtonDiscovery.org/ADDF or AlzDiscovery.org.
 


Thursday, January 12, 2017

Harrington Discovery Institute at University Hospitals announces 2017 grant funding to 11 physician-scientists

CLEVELAND –  The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, has announced the 2017 recipients of Harrington Scholar-Innovator Awards. The awards support breakthrough discoveries of physician-scientists whose research shows promise to advance the standard of care.
 
The Harrington Discovery Institute – part of The Harrington Project for Discovery & Development –fulfills an unmet need in academic medicine: to advance early breakthroughs into the clinical realm. Its focus on physician-scientist innovators from across the country and the UK creates opportunity to transform the best innovation regardless of institution affiliation.      
 
In addition to financial support awarded to the winners, the Institute provides direction from leaders in the pharmaceutical industry who are charged with overseeing therapeutic development of Scholar programs. While working with the Institute, physician-scientists (and their institutions) retain the intellectual property for their work.
 
“Our scholars tell us that the guidance they receive from members of the Harrington Innovation Support Center is absolutely the most valuable part of their time with us—of even greater value than the money,” said Jonathan Stamler, MD, President of the Harrington Discovery Institute. “Research institutions and non-profit endeavors do not typically provide strong pharmaceutical capability. Technology languishes for lack of know-how.  We believe that if we can marry the best science with the best practices, we should be able to more effectively advance discovery.”
 
The selected scholars have access to several rounds of capital (up to a total of $700,000) through their affiliation with the Harrington Discovery Institute to support the transition of their work into the private sector. Scholars are then free to approach investors of their choice to underwrite the commercialization of their work or they can have facilitated access to BioMotiv, the mission-aligned development company that also is part of The Harrington Project. However, there are no obligations on either side.  
 
The 2017 Harrington Scholar-Innovator grant recipients are:
 
Paul Bollyky, MD, PhD – Stanford University – A novel drug for Type I Diabetes
 
Ambrose Cheung, MD – Geisel School of Medicine at Dartmouth – A novel treatment against MRSA and other Gram+ bacterial infections
 
Giulio Draetta, MD, PhD – The University of Texas MD Anderson Cancer Center – A new therapy and first in-human trials for pancreatic cancer
 
Seth Field, MD, PhD – University of California San Diego – A novel pathway causing cancer
 
Todd Gould, MD – University of Maryland – A new medicine for depression
 
John Letterio, MD – Case Western Reserve University/University Hospitals – A promising drug for Alzheimer’s disease, stroke and cancer
 
David Lombard, MD, PhD – University of Michigan – A new strategy in melanoma therapy
 
Daruka Mahadevan, MD, PhD – University of Arizona – A novel class of cancer drugs and radiation sensitizers
 
Deepak Nijhawan, MD, PhD



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.